All In Biotech

Drug Trial Radar · NCT07280377

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

A Phase 1 / 2 Multiple-indication Biomarker, Safety, and Efficacy Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Last checked: Nov 19, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

122

Planned (sponsor's estimate)

Start

Oct 27, 2021

Primary completion

Jul 30, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Oncolytics BiotechIndustry
Sponsor type
Industry
Collaborators
Crolll Gmbh; AIO-Studien-gGmbH
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate \[ORR; Cohorts 1,2, 4,and 5\] and disease control rate \[DCR; Cohort 3\]) in patients with advanced or metastatic gastrointestinal (GI) tumors. Cohorts 1-4 are not randomized; however, Cohort 5 is comprised of two treatment arms to which patients are randomized in a 1:1 ratio.

Conditions

  • Anal Cancer Metastatic
  • Squamous Cell Carcinoma of the Anus Stage Unspecified
  • Pancreatic Cancer Metastatic
  • Unresectable Pancreatic Carcinoma

Interventions

  • PelareorepDrug

    Pelareorep 4.5 x 10\^10 TCID50 via 1-hour IV infusion

  • AtezolizumabDrug

    Atezolizumab 840 mg IV infusion

  • Gemcitabine and nab-paclitaxelDrug

    Gemcitabine (1,000 mg/m2) and nab-paclitaxel (125 mg/m2)

  • Trifluridine TipiracilDrug

    Trifluridine/tipiracil administered at a 35 mg/m2 dose orally twice daily

  • mFOLFIRINOX Treatment RegimenDrug

    mFOLFIRINOX- IV oxaliplatin 85 mg/m2; IV leucovorin 400 mg/m2; IV irinotecan 150 mg/m2; 5-FU 2400 mg/m2 by 46-hour infusion, per local standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR) for Cohort 1, 2, 4, and 5Time frame: At week 16 (within each cohort)
  2. Disease Control Rate (DCR) - Cohort 3Time frame: at week 16
  3. Overall Survival (OS) - Cohort 5Time frame: Cohort 5: From the date of randomization through long term follow up at 2 years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Nationales Centrum für Tumorerkrankungen Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany

  • SLK-Kliniken Heilbronn GmbH

    Heilbronn, Baden-Wurttemberg, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Baden-Wurttemberg, Germany

  • Universitätsklinikum Ulm

    Ulm, Baden-Wurttemberg, Germany

  • Gemeinschaftspraxis Dr. Med Bernhard Heinreich

    Augsburg, Bavaria, Germany

  • Klinikum der Universität München

    München, Bavaria, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Asklepios Kliniken Hamburg GmbH

    Hamburg, Free and Hanseatic City of Hamburg, Germany

  • Krankenhaus Nordwest

    Frankfurt am Main, Hesse, Germany

  • St. Josef-Hospìtal, Bochum

    Bochum, North Rhine-Westphalia, Germany

  • Universitätsmedizin Mainz

    Mainz, Rhineland-Palatinate, Germany

  • Caritasklinikum Saarbrücken St. Theresia

    Saarbrücken, Saarland, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, Saxony, Germany

  • Universität Leipzig

    Leipzig, Saxony, Germany

  • Charité Universitätsklinikum Berlin

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.